MK-0616: Clinical Trials

3 trials of MK-0616, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 completed. 3 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Recruiting 2, Completed 1
Phase 31Recruiting 1

Follow MK-0616: new trials by email Literature Review of MK-0616 trials Research Report on MK-0616

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
MK-7262, Enlicitide, Placebo for MK-7262 - Lipoprotein(a)
Phase 2RecruitingMerck Sharp & Dohme LLC7502026-06-302026-11-12
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Enlicitide Decanoate, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC1532025-08-212026-11-12
A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)
Enclitide Chloride, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 2CompletedMerck Sharp & Dohme LLC3812022-03-102024-12-09

Conditions studied

Hypercholesterolemia (1)  ·  Hyperlipoproteinemia Type II (1)

Sponsors

Merck Sharp & Dohme LLC (3)

Countries

Germany (3)  ·  Japan (3)  ·  United States (3)  ·  Colombia (2)  ·  Mexico (2)  ·  Netherlands (2)  ·  Norway (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Chile (1)  ·  China (1)

Results publications

PMID 36889610

NIH funding

2025 (1)